Cancer Archives

imfinzi astrazeneca breakthrough designation

News and Trends 11 Sep 2017

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

UPDATE: 11/09/2017: AstraZeneca has presented impressive results at ESMO that show Imfinzi adding 11 months to patient survival, or decreasing the risk of progression by 48%, in Stage 3 NSCLC. This indication represents a sizable market segment — about half of lung cancer — and Imfinzi’s first-line position could make it a blockbuster. Original Publication: […]

September 11, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 8 Sep 2017

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

GSK has backed Adaptimmune in the development of their adaptable NY-ESO SPEAR T cell cancer therapy, causing an 11% jump in their premarket value. Adaptimmune has received support from GlaxoSmithKline (GSK) for the development of their NY-ESO SPEAR T cell, which will hopefully treat a range of different cancers. The British pharma giant will pay milestones of up to £48M (€52M) […]

September 8, 2017 - 2 minutesmins - By Alex Dale

News and Trends 8 Sep 2017

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

The FDA has granted breakthrough therapy designation to Regeneron and Sanofi for cemiplimab, just a month after announcing they will part ways soon. Cemiplimab (REGN2810) has been granted breakthrough therapy designation by the FDA for the treatment of metastatic cutaneous squamous cell carcinoma (CSCC), considered the second deadliest skin cancer after melanoma. The antibody is a […]

September 8, 2017 - 1 minutemin - By Clara Rodríguez Fernández

News and Trends 7 Sep 2017

Spanish Biotech Receives €4.2 Million To Continue Development of Anti-Cancer Peptide

Investment will allow Peptomyc to continue the development of their peptide cancer therapy with reduced side effects. Peptomyc gained €4.2M from a group of investors led by Alta Life Sciences at Series A of fundraising. Peptomyc is part of the growing biotech hub in Barcelona, Spain. A spin-out was formed following research carried out at […]

September 7, 2017 - 2 minutesmins - By Alex Dale

News and Trends 7 Sep 2017

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

Nucana Biomed has filed for a Nasdaq IPO in which it expects to raise up to $115M (€96M) to support the progression of its oncology pipeline. Nucana Biomed, a biotech based in Edinburgh, specializes in using phosphoramidate chemistry to upgrade nucleoside analogs, a common form of chemotherapy drugs. With its pipeline reaching late stages of […]

September 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 7 Sep 2017

CAR-T is Nearly Here: How Will It Be Delivered?

As we anticipate the first-ever CAR-T therapy market approval we look at the important aspect of treatment delivery and viral vector strategies. Cell and gene therapy is increasingly coming into its own with some of the major pharma players releasing big headlines. GlaxoSmithKline (GSK) released the first ex vivo stem cell therapy in May 2016 […]

September 7, 2017 - 4 minutesmins - By External Contributor

News and Trends 6 Sep 2017

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

MSD is back in the RNA field with the acquisition of Rigontec, a German biotech harnessing RNA interference to make the immune system attack cancer cells. After selling selling Sirna Therapeutics three years ago for almost a tenth of the acquisition price, it seemed like MSD was out of the RNA field. However, the big […]

September 6, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 6 Sep 2017

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Gilead has just splashed out $12 billion for Kite Pharma, and the FDA is currently reviewing Novartis’ Marketing Approval Application for the first-ever CAR-T therapy. I sat down with Gregg Sando of Cell Medica to hear the perspective of a biotech vying for a piece of the pie. Though he spent 20 years in investment […]

September 6, 2017 - 6 minutesmins - By Evelyn Warner

AMAL Therapeutics Cancer Vaccine Series B

News and Trends 5 Sep 2017

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

AMAL Therapeutics has raised €8M to push its colorectal cancer vaccine ATP128 into clinical trials and keep developing its tumor vaccine pipeline. AMAL Therapeutics, a young biotech based in Geneva, is getting a boost for its pipeline of cancer vaccines thanks to a new funding round. The first tranche of its Series B fundraising has gathered €8M (CHF 8.8M) […]

September 5, 2017 - 1 minutemin - By Clara Rodríguez Fernández

CAR T cell therapy FDA approval cancer Novartis Kymriah CTL019

News and Trends 31 Aug 2017

The FDA Approves the First CAR-T Cell Therapy for Cancer

The FDA has approved Novartis’ CAR-T therapy Kymriah, opening the way for a new generation of cell therapy treatments against cancer. Novartis’ Kymriah (tisagenlecleucel), formerly known as CTL019, has become the first gene-modified cell therapy approved in the US. The FDA has approved the therapy for relapsing B-cell acute lymphoblastic leukemia (ALL) in children and young […]

August 31, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Aug 2017

Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks

European CAR-T stocks have jumped following Gilead’s announcement that it will acquire Kite Pharma, Novartis’ main competitor to launch the first therapy. Yesterday, Gilead bought a $11.9Bn (€9.9Bn) ticket to enter the final leg of the race to launch the first CAR-T therapy, a technology that is expected to change how cancer is treated. Despite the technology’s […]

August 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Apeiron biologics eib efsi funding neuroblastoma

News and Trends 28 Aug 2017

Austrian Biotech Gets €25M of EU Funding to Fight Rare Childhood Cancer

Apeiron Biologics has been granted financing of €25M from the European Investment Bank (EIB) to support the development of new treatments for cancer. Apeiron Biologics is a biotech based in Vienna focused on developing immuno-oncology treatments designed to make the immune system attack cancer cells. The EIB has decided to support the company’s research of a […]

August 28, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Cancer

UPDATE: AstraZeneca’s Checkpoint Inhibitor Could be a Lung Cancer Blockbuster

GSK wants in on Adaptimmune’s Adaptable T cell Cancer Treatment

Checkpoint Inhibitor from Regeneron and Sanofi gets Priority After Breakup

Spanish Biotech Receives €4.2 Million To Continue Development of Anti-Cancer Peptide

Scottish Oncology Biotech Aims for €96M IPO in the Nasdaq

CAR-T is Nearly Here: How Will It Be Delivered?

MSD Offers €464M to Buy German Biotech Fighting Cancer with RNA

The CAR-T Race is Far from Over: This CEO is Exploring a New Avenue

Swiss Biotech Raises €8M in First Closing of Series B to Develop Cancer Vaccines

The FDA Approves the First CAR-T Cell Therapy for Cancer

Gilead’s €10Bn Buyout of Kite Pharma Shakes European CAR-T Stocks

Austrian Biotech Gets €25M of EU Funding to Fight Rare Childhood Cancer

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!